Combination of Capecitabine and Ixabepilone Proves Effective in Resistant Triple-Negative Breast Cancer

Article

The combination of capecitabine (Xeloda) and ixabepilone (Ixempra) appears to be robust in patients with the triple-negative breast cancer phenotype. In heavily pretreated metastatic breast cancer patients, the regimen yielded an overall response rate of 27% and median progression-free survival of 4.1 months, according to a subset analysis of 187 patients from a larger randomized phase III trial of capecitabine with and without ixabepilone.

The combination of capecitabine (Xeloda) and ixabepilone (Ixempra) appears to be robust in patients with the triple-negative breast cancer phenotype. In heavily pretreated metastatic breast cancer patients, the regimen yielded an overall response rate of 27% and median progression-free survival of 4.1 months, according to a subset analysis of 187 patients from a larger randomized phase III trial of capecitabine with and without ixabepilone.

Hope Rugo, MD
Photo Courtesy SABCS/Todd Buchanan 2007

"This study was an attempt to cull out this very resistant group of patients, which represented 25% of patients in our larger trial. These patients have limited treatment options, and this was quite an effective treatment for them," said principal investigator Hope Rugo, MD, of the University of California, San Francisco School of Medicine. Dr. Rugo pointed out that "triple-negative" breast cancers -- those that are estrogen receptor-negative, progesterone receptor-negative, and HER2-negative -- are associated with an aggressive phenotype and poor prognosis as a result of their increased mitotic index, central necrosis, proportion of apoptotic cells, and other high-risk pathological features. Patients with triple-negative tumors develop their disease at an earlier age, are more likely to relapse, and tend to develop visceral and brain metastases as well as bone metastases, compared with other breast cancer subtypes. "Such patients have worse survival compared with other subgroups and fewer effective treatment options, since they are not candidates for either hormonal or HER2-targeted therapy," she said. "We need new agents with novel mechanisms of action for this population that is so difficult to treat." The study population was part of a prospective multicenter phase III trial of 752 women with metastatic breast cancer resistant to taxanes and pretreated with or resistant to anthracyclines. Patients were randomized to capecitabine monotherapy 1250 mg/m2 twice daily on days 1 to 14 of a 21-day cycle, or to capecitabine 1000 mg/m2 twice daily on days 1 to 14 plus ixabepilone 40 mg/m2 on day 1 of a 21-day cycle. For these triple-negative patients, progression-free survival was prolonged to 4.1 months with the combination, compared with 2.1 months with capecitabine alone, for a 32% reduction in risk. Overall response rates also increased with the combination, to 27% from 9% with monotherapy. The differences between the arms reflected those observed in the larger population, though outcomes were better overall in the non-triple-negative group. "Nearly half this patient group had received two or more lines of therapy. If you give this combination earlier, it is quite likely that you will get an even better response and, more important, a longer time to progression," Dr. Rugo said, noting that this has been shown in subset analyses. The combination was relatively well tolerated. The most common grade 3 or 4 adverse events were neutropenia (68%) and peripheral sensory neuropathy (21%). Both were manageable with dose adjustments. "Interestingly, the neuropathy that occurs with this regimen resolves very quickly when you stop the drug, unlike with taxanes. Within 6 weeks, patients return to baseline, and if you dose-reduce ixabepilone, it does not recur," she said.

Disclosures:

The author(s) have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.

Recent Videos
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
Related Content